Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies.
Thirty-six patients with ovarian cancer were treated with intraperitoneal I-131 labeled monoclonal antibodies to tumor associated antigens. The activity of I-131 administered was increased from 20 mCi to 158 mCi and the pharmacokinetics and toxicity evaluated. Five patients who had developed HAMA (Human Antimouse Antibodies) were retreated, and the pharmacokinetics and toxicity of the first and second treatment compared. Patients receiving their first therapy (HAMA negative), had a maximum of 25% (range 19.8-39.8%) of the injected activity in their circulation. This was accompanied by severe marrow suppression at I-131 activities over 120 mCi. The 5 HAMA positive patients had only 5% injected activity in the systemic circulation (range 3.8-6%), with rapid urinary excretion and neglible marrow suppression. In 31 patients with assessable disease there were no responses in 8 patients with gross disease (nodules greater than 2 cms), partial responses in 2 out of 15 patients with nodules less than 2 cms, and complete responses in 3 out of 6 patients with microscopic disease. The non specific radiation dose to the peritoneal cavity was estimated to be less than 500 cGy by lithium fluoride TLD, and could not be expected to account for the responses seen.
Stewart
J S
JS
Imperial Cancer Research Fund, Royal Postgraduate Medical School, London, England.
Hird
V
V
Snook
D
D
Sullivan
M
M
Hooker
G
G
Courtenay-Luck
N
N
Sivolapenko
G
G
Griffiths
M
M
Myers
M J
MJ
Lambert
H E
HE
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000917:Antibody Formation; D000951:Antigens, Neoplasm / Q000276:immunology; D001853:Bone Marrow / Q000528:radiation effects; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D051379:Mice / Q000276:immunology; D010051:Ovarian Neoplasms / Q000276:immunology / Q000532:radiotherapy* / Q000601:surgery
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D007457:Iodine Radioisotopes